June 2013, Vol 4, No 5

Researchers have analyzed the genetic makeup of hundreds of endometrial tumors that may lead to targeted therapies for subpopulations of patients with this deadly cancer.
Read Article

With the Third Annual Con­ference of the Associ­ation for Value-Based Cancer Care (AVBCC) held in May in Florida and the 2013 Annual Meeting of the American Society of Clinical Oncology concluding in June in Chicago, it is tempting to consider which of the many presentations, abstracts, and reports were most impactful or will have the greatest influence on how oncologists think about, diagnose, and treat patients with cancer.
Read Article

Chicago, IL—Previous trials of maintenance therapy for patients with ovarian cancer have failed to show improved survival. A study presented at the 2013 American Society of Clinical Oncology annual meeting is the first successful phase 3 trial in this setting, showing that the targeted therapy pazopanib (Votrient) extended progression-free survival (PFS) by a median of 5.6 months in women with ovarian cancer.
Read Article

Chicago, IL—Inappropriate deviation from evidence-based standards of care for cancer raises costs in excess of $25,000 per patient, stated Arlene A. Forastiere, MD, Senior Vice President of Medical Affairs at eviti, Inc, Philadelphia, PA, in a poster presented at the 2013 American Society of Clinical Oncology annual meeting.
Read Article

Hollywood, FL—Genomic profiling of individual tumors represents a paradigm shift in oncology and holds great promise for patients, according to Gary Palmer, MD, JD, MBA, MPH, Senior Vice President, Medical Affairs and Commercial Development, Foun­dation Medicine, who described this new genomic assay at the Third Annual Conference of the Association for Value-Based Cancer Care.
Read Article

Hollywood, FL— A community oncology medical home headed by Barbara L. McAneny, MD, Chief Executive Officer and Managing Partner of the New Mexico Cancer Center, Albuquerque, is a good example of how putting patients first can be good for patient care and good for the bottom line.
Read Article

Page 4 of 4